Thyroid Cancer Trial, Recruiting NCT05575440 Sponsor: Mayo Clinic Condition: Thyroid Cancer
Back to Thyroid Cancer

Thyroid Cancer Trial, Recruiting

NCT05575440
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with papillary or follicular thyroid cancer, confirmed by a tissue biopsy
  • Your doctor has recommended you have a standard total body iodine scan using a radioactive substance called I-123
  • You are willing to have an additional type of scan called an 18F-TFB PET/CT scan after your regular iodine scan
  • You are generally well enough to carry out daily self-care activities (confirm with trial site if unsure about this fitness level)
  • You are able to lie still on a scanner table for up to 65 minutes
  • You are 18 years of age or older
  • You are able to understand and are willing to sign a written consent form
  • You are not currently pregnant

Who may not be able to join:

  • You have had a contrast-enhanced CT scan within the last 4 weeks
  • You have taken a heart medication called Amiodarone within the last 4 months
  • You have consumed iodine supplements, kelp tablets, Lugol's iodine, or potassium iodide within the last 2 weeks
  • You are unable to lie flat or stay still, or cannot tolerate a PET scan
  • You have applied iodine-containing skin products such as betadine, iodoform, or self-tanning products to your skin within the last 2 weeks
  • Your TSH (thyroid hormone) level is below 25 if you are using medication withdrawal as part of your preparation for the scan (confirm with trial site)
  • You have taken anti-thyroid medication within the last week
  • You are currently breastfeeding
  • You have a positive pregnancy test

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
22 April 2022
Est. completion
1 May 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Descriptive summaries of detected lesions; Conspicuities and diagnostic confidence scores for a given lesion

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov